Carsten Denkert

Has grant

Philipps-Universität Marburg
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

TransLUMINAL-B

Open Date: 2015-07-01

Close Date: 2018-06-01

Grant: Close

Transcan UGI-1

Open Date: 2014-01-01

Close Date: 2016-01-01

Grant: Close

RESPONSIFY

Open Date: 2012-01-01

Close Date: 2015-01-01

Grant: Close

ARROWS

Open Date: 2009-01-01

Close Date: 2012-01-01

Grant: Close

METAcancer FP7

Open Date: 2008-01-01

Close Date: 2011-01-01

Articles (22)

IDFS by HER2 IHC score at definitive surgery (derived from samples used for eligibility and exploratory purposes). IDFS, invasive disease-free survival; IHC, immunohistochemistry; T-DM1, trastuzumab emtansine.

Year:

2025

HER2, PD-L1, and Five-Gene Signature Quartile Analysis. IDFS by HER2 gene expression quartile (A) in the trastuzumab arm; and (B) in the T-DM1 arm; (C) treatment effect on IDFS by HER2 gene expression quartile; (D) effect of HER2 gene expression quartile on IDFS; IDFS by PD-L1 gene expression quartile (E) in the trastuzumab arm; and (F) in the T-DM1 arm; (G) treatment effect on IDFS by PD-L1 gene expression quartile; (H) effect of PD-L1 gene expression quartile on IDFS; IDFS by five-gene signature (i.e., PD-L1/granzymeB/CD8/IFNγ/CXCL9) gene expression quartile (I) in the trastuzumab arm; and (J) in the T-DM1 arm; (K) treatment effect on IDFS by five-gene signature gene expression quartile; (L) effect of five-gene signature gene expression quartile expression on IDFS. Each expression quartile (quartile 2, quartile 3, and quartile 4) is compared to the lowest quartile (quartile 1). The analyses are unstratified and adjusted using a Cox regression model that includes percent tumor in marked area, clinical stage at presentation, hormone receptor status, type of preoperative HER2-directed therapy, and pathologic nodal status. HER2, human epidermal growth factor receptor 2; IDFS, invasive disease-free survival; IFNγ, interferon gamma; Q, quartile; T-DM1, trastuzumab emtansine.

Year:

2025

Comparison of HER2 expression intensity in paired pre-NAT (i.e., before surgery) and post-NAT surgical samples. HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; NAT, neoadjuvant therapy.

Year:

2025

Comparison of IDFS outcomes in the ITT population compared to the (A) RNA-evaluable population (REP) (including pre- and post-NAT surgical samples) and in patients with (B) pre-NAT REP samples (left) or post-NAT surgical REP samples (right). HER2, human epidermal growth factor receptor 2; IDFS, invasive disease-free survival; IHC, immunohistochemistry; ITT, intent-to-treat; NAT, neoadjuvant therapy; T-DM1, trastuzumab emtansine.

Year:

2025

Comparison of baseline patient and disease characteristics assessed at eligibility in the ITT population versus in those with mRNA data derived from pre-NAT or post-NAT surgical samples (RNA-evaluable population). Note: the pre-NAT and post-NAT samples are not paired.

Year:

2025

Comparison of pre-NAT and post-NAT surgical RNA-evaluable samples. (A) ERBB2 (i.e., HER2), CD274 (i.e., PD-L1), checkpoint inhibitor signature (i.e., PD-L1/PD-L2/IDO), CD8A (i.e., CD8), TEFF signature CD8/granzymeA/granzymeB/perforin/IFNγ), three-gene signature (i.e., PD-L1/IFNγ/CXCL9), five-gene signature (i.e., PD-L1/granzymeB/CD8/IFNγ/CXCL9), Th1 cytokine signature (i.e., CXCL9/CXCL10/CXCL11), and B cell gene expression. (B) Frequency of AIMS PAM50 subtypes overall and by hormone receptor status. (C) Frequency of AIMS PAM50 subtypes by level of HER2 protein expression assessed by IHC in pre- and post-NAT samples. (D) Frequency of AIMS PAM50 subtypes by level of HER2 gene expression in pre- and post-NAT samples. (E) Hallmark gene sets enriched for genes upregulated in post-NAT surgical versus pre-NAT samples (adjusted P

Year:

2025

Prognostic value for IDFS by treatment arm of biomarker gene expression levels (>median vs. ≤median and continuous) in post-NAT surgical RNA-evaluable tissue samples. Analysis is adjusted for tumor content. One sample could not be included because there was insufficient information on tumor content.

Year:

2025

Comparison of HER2 expression heterogeneity in paired pre-NAT (i.e., before surgery) and post-NAT surgical samples. Patients were categorized according to whether HER2 staining was focal (

Year:

2025

Figure S8 depicts GSEA for Millstein sub-signatures in the Charité cohort. Gene sets were incrementally increased by one gene at thetime (see color code). X-axis shows the NES and only the full 101-gene signature was significantly enriched.

Year:

2025

Purpose: The late-stage diagnosis and the aggressiveness of high-grade serous tubo-ovarian carcinoma (HGSC) often result in poor survival outcomes, yet some patients exhibit an exceptionally long survival rate. This study aimed to identify molecular profiles associated with long-/short-term survival in HGSC, with the goal of better understanding protective factors and developing new treatments. Experimental Design: To discover molecular drivers causing the aggressiveness of HGSC, tumor samples from 12 long-term HGSC survivors (>7 years overall survival) and 12 short-term survivors ( Results: Besides known molecular cancer drivers and indicators of poor prognosis, we identified specific transcriptional changes between short- and long-term survivors of HGSC, which indicate that immune processes play a fundamental role in long-term survivors. Our computational analysis reveals an important role for the ensemble of IFN-γ signaling and the RFX transcription factors, as well as the immune cell composition of the tumor microenvironment. Conclusions: Specific immunologic requirements involving IFN-γ signaling and affected pathways seem to be relevant for long-term survival in the generally considered nonimmunogenic HGSC, necessitating further research to improve diagnostic strategies and targeted therapies.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (20)

alfonso valencia

Research Professor

Instituciò Catalana de Recerca i Estudis Avancats

SPAIN
View details

Eric Hahnen

-

GERMANY
View details

Ioana Braicu

Head of clinical and translational research

Charité - Universitätsmedizin Berlin

GERMANY
View details

Peter Sinn

Head, Division of Gynaecopathology

University Hospital

GERMANY
View details

Charles Edward Geyer Jr

Professor of Medicine in Division of Hematology/Medical Oncology

University of Pittsburgh

UNITED STATES
View details

Christine Solbach

Goethe University Frankfurt

GERMANY
View details

Judith Balmaña

Head

Hospital Universitari Vall d'Hebron

SPAIN
View details

Jalid Sehouli

Charité - Universitätsmedizin Berlin

GERMANY
View details

Mark Basik

McGill University

CANADA
View details

Terence Williams

City Of Hope National Medical Center

UNITED STATES
View details

Judith Lea Lindner

-

GERMANY
View details

Marcus Schmidt

Professor and Head of Molecular Oncology

University Medical Center

GERMANY
View details

Tanja Fehm

Professor

University Hospital Düsseldorf

GERMANY
View details

Thomas Karn

Goethe University Frankfurt

GERMANY
View details

Peter Fasching

-

GERMANY
View details

Guillermo Villacampa Javierre

Biostatistician

Vall d´Hebron Institute of Oncology

SPAIN
View details

Changxian Shen

City of Hope

UNITED STATES
View details

Peter Lucas

Professor and Vice Chair of Research

Mayo Clinic

UNITED STATES
View details

Violeta Serra

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

Paul Jank

Head of Translational Research Laboratory

-

GERMANY
View details